Indena has further expanded its existing GMP Pilot Plant for active pharmaceutical ingredients, doubling kilo lab LK2 for OEB 5 products and installed a 250-liter industrial hydrogenator. Indena is presenting these latest innovations at DCAT 2022.
Indena confirmed its move to improve the supply chain of escin and horse chestnut derivatives, successfully completing the registration of ESCIN (INCI: ESCIN; EC # 229-880-6, CAS # 6805-41-0, Registration 01-2120757334-53-0000) in accordance with the REACH regulation (EC) No 1907/2006 as lead registrant.
Indena, the Italian company focused on identification, development and production of high-quality active principles derived from plants, for use in the pharmaceutical, health-food and cosmetic industries, has received a grant from the Bill & Melinda Gates Foundation to work on a strategic project to improve new potential antimalarial therapies for children in disease- endemic countries.
Indena, an Italian company that provides identification, development and production of active principles derived from plants—for use in the pharmaceutical, health-food and personal care industries—is selling its cosmetics business to Givaudan to focus on core markets, including the pharma side of its operations.
Jaguar Health, a commercial stage pharmaceutical company focused on developing gastrointestinal products, said that Indena S.p.A., one of the two contract manufacturers of the active pharmaceutical ingredient (API) in crofelemer, has developed and implemented an improved crofelemer manufacturing process, effectively increasing yield and realizing reduced cost through increased manufacturing efficiencies while retaining the same phytochemical profile without compromising product quality, safety, purity and efficacy.
Indena says industry’s recognition of the high quality of Italian-made ingredients has driven investments in an HPAPI kilolab and a multi-purpose pilot plant near Milan.
The Indian Patent Office has refused patent protection for a medicine of Italian research firm Indena SPA to treat Mucositis, a painful inflammation that occurs after chemo or radiotherapy treatment for cancer, in India. The office also refused a pre-grant opposition filed by a scientist in the Council of Scientific and Industrial Research (CSIR), Delhi against the application.